



**Proteomics International**  
LABORATORIES LTD

**ASX Release**  
**31 January 2025**

**ASX code: PIQ**

## **Change of Company Secretary**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a pioneer in precision diagnostics, is pleased to announce the appointment of Tim Luscombe as Company Secretary, effective today.

This appointment follows the resignation of Karen Logan as Company Secretary, effective 31 January 2025. Ms Logan has served as Company Secretary of PIQ since July 2014, and the Board would like to thank Karen for her considerable contribution to Proteomics International over the past 10 years.

Mr Luscombe is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the Healthcare sector. He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr Luscombe currently serves as a CFO and Company Secretary for several ASX listed, public unlisted and private Healthcare companies. Mr Luscombe holds a Bachelor of Commerce from the University of Melbourne and a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

Mr Luscombe is responsible for communications with the ASX in relation to Listing Rule matters under ASX Listing Rule 12.6.

Authorised by the Chairman and the Managing Director of PIQ on behalf of the Board.

ENDS

### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

### **For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Investor Relations  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

**Proteomics International Laboratories Ltd**  
ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)